Which drug first? new study aims to improve breast cancer treatment order
NCT ID NCT07368543
First seen Jan 31, 2026 · Last updated May 15, 2026 · Updated 17 times
Summary
This study tests two powerful targeted drugs, sacituzumab govitecan (SG) and trastuzumab deruxtecan (T-DXd), in people with a specific type of advanced breast cancer (HER2-low/TROP2-high). The goal is to see which drug works better when given first, and what happens when patients switch to the other drug after the first stops working. About 216 adults will take part, and researchers will track how long the cancer is controlled. This is not a cure, but aims to improve disease control and guide treatment choices.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.